心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：接受右室流出道移植重建的女性妊娠结局

2018-06-07 MedSci MedSci原创

心血管右室流出道妊娠
关注

本研究的目的旨在评估接受右室流出道（RVOT）移植重建妇女的孕期预后结局。本研究纳入了196名18-50岁接受右室流出道（RVOT）移植重建的女性，并对其完全妊娠（孕期≥20周）的心脏、产科和胎儿的结局进行了评估。分析结果显示，有56名女性完成了89次完全妊娠，其中有84次（94.4%）的数据较完整，可分析。患者的平均年龄为29.6 ± 4.3岁，80名患者的纽约心功能分级是I或II。最常见的疾病

本研究的目的旨在评估接受右室流出道（RVOT）移植重建妇女的孕期预后结局。

本研究纳入了196名18-50岁接受右室流出道（RVOT）移植重建的女性，并对其完全妊娠（孕期≥20周）的心脏、产科和胎儿的结局进行了评估。分析结果显示，有56名女性完成了89次完全妊娠，其中有84次（94.4%）的数据较完整，可分析。患者的平均年龄为29.6 ± 4.3岁，80名患者的纽约心功能分级是I或II。最常见的疾病诊断是法洛氏四联症，所有患者妊娠后均存活，有2例（2.4%）心衰、1例（1.2%）感染（绒毛膜羊膜炎）和3例（3.6%）先兆子痫的发生。所有胎儿均顺利出生，平均孕周是38.4周，平均体重为2930g，17例（20.2%）为低于胎龄儿，20例（23.8%）为早产儿，2（2.4%）例出现新生儿死亡。与一般人群相比，早产率和低于胎龄儿率要更高。

研究结果显示，接受右室流出道移植重建的女性可以顺利妊娠和分娩，但是早产率和低于胎龄儿率更高。

原始出处：

本文系梅斯医学(MedSci)原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854053, encodeId=7bc71854053d3, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Sep 08 23:43:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325855, encodeId=48f51325855c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392946, encodeId=625213929469d, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322257, encodeId=220d32225ed3, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:11 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322247, encodeId=4f8f32224e74, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Jun 07 13:14:51 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-09-08 hbwxf

    #JACC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1854053, encodeId=7bc71854053d3, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Sep 08 23:43:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325855, encodeId=48f51325855c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392946, encodeId=625213929469d, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322257, encodeId=220d32225ed3, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:11 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322247, encodeId=4f8f32224e74, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Jun 07 13:14:51 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-09 12498568m50暂无昵称

    #ACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1854053, encodeId=7bc71854053d3, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Sep 08 23:43:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325855, encodeId=48f51325855c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392946, encodeId=625213929469d, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322257, encodeId=220d32225ed3, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:11 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322247, encodeId=4f8f32224e74, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Jun 07 13:14:51 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-09 12498a1cm67暂无昵称

    #妊娠结局#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1854053, encodeId=7bc71854053d3, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Sep 08 23:43:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325855, encodeId=48f51325855c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392946, encodeId=625213929469d, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322257, encodeId=220d32225ed3, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:11 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322247, encodeId=4f8f32224e74, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Jun 07 13:14:51 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-07 天地飞扬

    了解一下.谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1854053, encodeId=7bc71854053d3, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat Sep 08 23:43:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325855, encodeId=48f51325855c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392946, encodeId=625213929469d, content=<a href='/topic/show?id=8c9f4492370' target=_blank style='color:#2F92EE;'>#妊娠结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44923, encryptionId=8c9f4492370, topicName=妊娠结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Sat Jun 09 03:43:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322257, encodeId=220d32225ed3, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jun 07 14:46:11 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322247, encodeId=4f8f32224e74, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Jun 07 13:14:51 CST 2018, time=2018-06-07, status=1, ipAttribution=)]
    2018-06-07 13718711b3m

    学习了.获益匪浅.感谢分享

    0

相关资讯

JACC：亚临床房颤的进展可增加心衰的发生风险

在有心血管疾病基础的老年人中，长期连续监测出短暂的亚临床房颤（SCAF）的发生率约为三分之一，本研究的目的旨在评估SCAF的进程与心衰发生的关系。本研究纳入了ASSERT临床研究中的患者，所有患者均≥65岁，有高血压疾病史，无房颤或起搏器的植入。最终筛选入415例SCAF在入组后1年内最长持续时间＞6min但≤24h的患者。经过平均2年时间的随访，有65例（15.7%）患者的SCAF发展为持续时间

Heart：缬沙坦治疗慢性心衰伴射血分数降低具有成本效益

慢性心衰伴射血分数降低（HF-REF）的发病率和死亡率均较高，本研究的目的旨在评估比较噻氯比利/缬沙坦和ACE抑制剂（ACEI）在治疗HF-REF中的成本-效益。本研究纳入分析了来自英国、丹麦和哥伦比亚数据库中的HF-REF患者，主要终点事件是成本-效益比值的增量（ICER）。分析结果显示，在英国，噻氯比利/缬沙坦的质量调整寿命（QALY）提高的成本是17100英镑，在丹麦和哥伦比亚，噻氯比利/缬

Heart：先心病患儿的很大摄氧量明显低于正常儿童

本研究的目的旨在评估先天性心脏病患儿的心肺功能与正常健康同龄儿童之间的差异，并寻找与最大摄氧量（VO2max）相关的临床特征。本次多中心横断面研究纳入了798名儿童（496名先心病患儿和302名正常儿童），并对其进行了完整的心肺功能测试（CPET）。分析结果显示，先心病组和对照组的平均VO2max预测值分别为93%±20%和107%±17%，先心病患儿的VO2max要明显更低（37.8±0.3vs

盘点：JACC6月第1期研究一览

1. SGLT-2I能明显降低患者死亡和心衰发生风险DOI: 10.1016/j.jacc.2018.01.085既往研究显示钠葡萄糖共转运蛋白-2抑制剂（SGLT-2I）可以降低患者的死亡率和心衰发生率。本研究纳入了CVD-REAL临床研究中的2型糖尿病成年患者，并根据倾向性评分将患者分成SGLT-2I治疗组和其他降血糖药物（GLDs）。倾向性评分匹配后，每组各纳入了153078名患者，其中13

JACC：高敏肌钙蛋白的引入对心梗的发病率和预后结局的影响

本研究的目的旨在评估自从引入高敏心脏肌钙蛋白T（hs-cTnT）后，对首次心梗的诊断率和预后带来了什么影响。本研究纳入了87879例2009至2013年来自瑞典国家数据库中的所有首发心梗的患者，在研究期间，通过心脏肌钙蛋白诊断出的心梗患者为47133例，而通过hs-cTnT诊断出的心梗患者为40746例，从引入hs-cTnT后，心梗的发病率增加了5%（95% CI： 0%-10%），经过平均3.9

Heart：这类先心病手术不应在婴儿期进行！

部分性房室间隔缺损（pAVSD）修复术的时机一般是2-4岁，预后很好，但婴儿期的修复术预后会较差。本研究的目的旨在评估婴儿期的pAVSD手术对患者预后的影响。本研究纳入了1975-2015年接受pAVSD修复术治疗的患儿，并将婴儿（＜1岁）与年龄较大儿童进行了倾向性评分匹配分析。最终共纳入了430名患儿，其中17.4%为婴儿，与年龄较大儿童相比，婴儿发生左房室瓣反流（LAVV）、心衰和其他心脏疾病